Aclaris Therapeutics’ latest e-mail from today morning contained a link to the following press release:
Quite often, when Aclaris discusses hair loss disorders in its press releases, they only mention alopecia areata (an autoimmune disorder that is responsible for hair loss in 2 percent or so of hair loss sufferers). However, this time they specifically mention androgenetic alopeia (AGA) six different times in their press release so it was worth writing a post on this development. Around 98 percent all men who suffer from hair loss suffer from AGA.
If you are new to this subject matter, make sure to read all the past posts on this blog regarding Aclaris.
Aclaris’ Latest Patents
The two patents that were just granted to Aclaris are highly detailed and informative:
Patent Number 9,737,469 — covers the use of tofacitinib, baricitinib, ruxolitinib and decernotinib, specifically for treating androgenetic alopecia.
Patent Number 9,730,877 — covers the use of baricitinib for inducing hair growth and for treating hair loss disorders such as alopecia areata and androgenetic alopecia.
If you have time, I would encourage you to go through all the “US Patent Document” links in the upper part of the above two patent pages. Those reference documents go all the way from 1998 through 2016. If I had more time, I would search for “androgen” in all those documents and see what comes up.